Alpha Cognition Inc (ACOG)

Over the past six months, Alpha Cognition's stock price has decreased by approximately 40.87%, but increased by 19.64% between December 24, 2024, and December 23, 2025. Key events impacting the stock include the FDA approval and commercial launch of ZUNVEYL, Q2 and Q3 2025 earnings reports, participation in investor conferences, a public offering, a capital raise, and a corporate update highlighting strategic priorities for 2026.

The provided information does not explicitly detail demand seasonality for Alpha Cognition, Inc.'s products and services. Given that their primary product, ZUNVEYL, treats Alzheimer's disease, a chronic neurodegenerative condition, it is unlikely to experience significant seasonal fluctuations in demand. The demand for such treatments is generally driven by disease incidence, diagnosis rates, and patient access to medication rather than seasonal patterns.

Alpha Cognition, Inc. is a clinical-stage biopharmaceutical company based in Grapevine, Texas, and Vancouver, Canada, focused on developing treatments for neurodegenerative diseases like Alzheimer's, Cognitive Impairment with mild Traumatic Brain Injury (mTBI), and ALS. Their primary product is ZUNVEYL™ (benzgalantamine), an FDA-approved, delayed-release oral tablet for mild to moderate dementia of the Alzheimer's type. The company is also developing ZUNVEYL in combination with memantine, ALPHA-1062 sublingual and intranasal formulations, and gene therapy programs (GEMs) for various neurodegenerative diseases.

Alpha Cognition, Inc. develops treatments for patients in the United States and Canada. The company is also expanding its global reach through licensing agreements, including an exclusive agreement with China Medical System Holdings Limited (CMS) for ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand.

Alpha Cognition's brand reputation has been positively influenced by the FDA approval and commercial launch of ZUNVEYL, as well as ongoing preclinical development in other neurodegenerative diseases. The company has received a consensus "Buy" rating from Wall Street analysts. Events affecting the company's reputation include the FDA approval of ZUNVEYL, positive pre-clinical data for ALPHA-1062 in mTBI, strong commercial progress of ZUNVEYL, a strategic licensing agreement with China Medical System, and analyst coverage and price targets.

Alpha Cognition Inc. has both institutional and individual owners. As of September 30, 2025, there were 35 institutional holders holding a total of 5,654,247 shares. Major institutional owners include Solas Capital Management, LLC, AWM Investment Company, Inc., and Ikarian Capital, LLC. The largest individual shareholder is John Prentiss Havens. Individual investors collectively control 53% of the company, while hedge funds own 20%.